Cita APA

Bailey, C. J., Del Prato, S., Wei, C., Reyner, D., & Saraiva, G. (2019). Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes Obes Metab.

Chicago Style Citation

Bailey, Clifford J., Stefano Del Prato, Cheryl Wei, Daniel Reyner, i Gabriela Saraiva. "Durability of Glycaemic Control With Dapagliflozin, an SGLT2 Inhibitor, Compared With Saxagliptin, a DPP4 Inhibitor, in Patients With Inadequately Controlled Type 2 Diabetes." Diabetes Obes Metab 2019.

Cita MLA

Bailey, Clifford J., et al. "Durability of Glycaemic Control With Dapagliflozin, an SGLT2 Inhibitor, Compared With Saxagliptin, a DPP4 Inhibitor, in Patients With Inadequately Controlled Type 2 Diabetes." Diabetes Obes Metab 2019.